Soleno Therapeutics(US:SLNO) Globenewswire·2026-03-21 00:00Core Viewpoint - The lawsuit against Soleno Therapeutics, Inc. alleges that the company misrepresented safety concerns related to its product DCCR, leading to significant financial losses for investors during the class period from March 26, 2025, to November 4, 2025 [4]. Group 1: Lawsuit Details - The lawsuit claims that Soleno downplayed and concealed safety concerns regarding DCCR, particularly issues related to excess fluid retention in clinical trial participants [4]. - It is alleged that the administration of DCCR posed greater safety risks than disclosed, affecting its commercial viability and leading to undisclosed risks such as patient discontinuation rates and prescriber reluctance [4]. - Investors who suffered losses have until May 5, 2026, to request lead plaintiff appointment, which allows them to oversee the litigation on behalf of the class [2]. Group 2: Impact on Stock Price - Following a report by Scorpion Capital on August 15, 2025, which labeled DCCR as overpriced and potentially unsafe, Soleno's share price fell by $5.73, or approximately 7.41%, from $77.36 to $71.64 [5]. - On September 10, 2025, after a patient death was reported related to DCCR, the stock price dropped by $10.20, or about 14.53%, from $70.21 to $60.01 [6]. - During a quarterly earnings call on November 4, 2025, Soleno disclosed an 8% discontinuation rate for DCCR due to adverse effects, resulting in a significant share price decline of $16.98, or approximately 26.59%, from $63.85 to $46.87 [7].